Welcome to our dedicated page for INVITRO INTL news (Ticker: $IVRO), a resource for investors and traders seeking the latest updates and insights on INVITRO INTL stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect INVITRO INTL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of INVITRO INTL's position in the market.
InVitro International reported positive second quarter FY '24 results with sales of $210,615, up 5.8% from the same period in FY '23, and net income of $47,674. First half FY '24 sales increased 3.4% to $422,240, with a net income of $65,342 compared to losses in FY '23. The company is planning an uplisting to OTCQB to enhance visibility and credibility with potential M&A targets.